AbbVie’s Rinvoq hits target in psoriatic arthritis sub-population at Phase 3
pharmafile | February 6, 2020 | News story | Research and Development | AbbVie, Rinvoq, pharma, psoriatic arthritis
AbbVie has unveiled new Phase 3 data on its selective and reversible JAK inhibitor Rinvoq (upadacitinib) in the treatment of active psoriatic arthritis in adults who have responded inadequately or are intolerant to one or more non-biologic disease modifying anti-rheumatic drugs (DMARDs).
The results revealed that 71% of patients receiving 15mg Rinvoq and 79% receiving 30mg achieved an ACR20 response after 12 weeks of treatment compared to 36% with placebo, meeting the trial’s primary endpoint. Furthermore, Rinvoq proved non-inferior to adalimumab after 12 weeks in the 15mg dose, while the 30mg dose proved superior.
An ACR50 response was achieved after 12 weeks by 38% with 15mg and 52% with 30mg compared to 13% with placebo, while ACR70 was achieved by 16% and 25% respectively compared to 2% with placebo.
Skin symptoms were also reduced in both groups, with 62% and 63% of the 15mg and 30mg groups achieving a 75% improvement as measured by the Psoriasis Area Severity Index (PASI 75).
“The results of SELECT-PsA 1 showed that both doses of upadacitinib demonstrated significantly greater efficacy in joint and skin symptoms, as well as inhibition of radiographic progression, compared to placebo,” remarked Dr Professor Iain McInnes, University of Glasgow Institute of Infection, Immunity & Inflammation. “These data are encouraging and add to the growing body of evidence that upadacitinib has the potential to improve outcomes for people living with psoriatic arthritis.”
Dr Michael Severino, Vice Chairman and President at AbbVie, also commented on the results: “Patients living with psoriatic arthritis often suffer from joint pain, stiffness and fatigue, impacting their ability to work and lead a physically active life. The results of this large Phase 3 study further support the potential of Rinvoq to help these patients. We look forward to sharing these data with regulatory bodies around the world to support our application for label expansion for Rinvoq to include adult patients with active psoriatic arthritis.”
Matt Fellows
Related Content
Medincell and AbbVie enter agreement for development of next-generation injectables
Medincell and AbbVie have announced that they have entered into a collaboration to co-develop and …
AbbVie to acquire Landos Biopharma for approximately $137.5m
AbbVie and Landos Biopharma have announced that they have entered into a definitive agreement under …
AbbVie and Tentarix collaborate on oncology and immunology treatments
AbbVie and Tentarix Biotherapeutics have announced that they have entered a multi-year collaboration focused on …
